RC
ABUS icon

Rangeley Capital’s Arbutus Biopharma ABUS Stock Holding History

Rangeley Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.4M Hold
500,000
– – 2.19% 8
2026
Q1 		$2.25M Sell
500,000
-340,000
-40% -$1.49M 2.19% 9
2025
Q4 		$4.04M Hold
840,000
– – 3.36% 7
2025
Q3 		$3.81M Sell
840,000
-25,000
-3% -$91.8K 3.3% 9
2025
Q2 		$2.67M Sell
865,000
-484,000
-36% -$1.61M 3.19% 13
2025
Q1 		$4.71M Sell
1,349,000
-110,000
-8% -$367K 5.04% 3
2024
Q4 		$4.77M Buy
+1,459,000
New +$5.37M 4.28% 6

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rangeley Capital's ABUS Position: Q2 2026 in Review

Rangeley Capital held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 500,000 shares worth $2.4M. The position accounts for 2.19% of the portfolio, ranked #8.

Rangeley Capital first reported a position in ABUS in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.77M in Q4 2024. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Rangeley Capital held 500,000 shares of Arbutus Biopharma worth $2.4M as of Q2 2026.
  • Rangeley Capital left its Arbutus Biopharma share count unchanged in Q2 2026.
  • Arbutus Biopharma made up 2.19% of Rangeley Capital's portfolio in Q2 2026, its #8 holding.
  • Rangeley Capital first reported a position in Arbutus Biopharma in Q4 2024 and has held it in 7 quarters since.
  • Rangeley Capital's Arbutus Biopharma position peaked at $4.77M in Q4 2024.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.